Your browser doesn't support javascript.
loading
High-dose, high-frequency infliximab: A novel treatment paradigm for hidradenitis suppurativa.
Ghias, Mondana H; Johnston, Andrew D; Kutner, Allison J; Micheletti, Robert G; Hosgood, H Dean; Cohen, Steven R.
Afiliación
  • Ghias MH; Division of Dermatology, Department of Internal Medicine, Albert Einstein College of Medicine, Bronx, New York.
  • Johnston AD; Division of Dermatology, Department of Internal Medicine, Albert Einstein College of Medicine, Bronx, New York.
  • Kutner AJ; Division of Dermatology, Department of Internal Medicine, Albert Einstein College of Medicine, Bronx, New York.
  • Micheletti RG; Departments of Dermatology and Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.
  • Hosgood HD; Department of Epidemiology and Population Health, Albert Einstein College of Medicine, Bronx, New York.
  • Cohen SR; Division of Dermatology, Department of Internal Medicine, Albert Einstein College of Medicine, Bronx, New York. Electronic address: srcohen@montefiore.org.
J Am Acad Dermatol ; 82(5): 1094-1101, 2020 May.
Article en En | MEDLINE | ID: mdl-31589948

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Hidradenitis Supurativa / Infliximab / Anticuerpos Monoclonales Tipo de estudio: Etiology_studies / Incidence_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Adult / Female / Humans / Male / Middle aged Idioma: En Revista: J Am Acad Dermatol Año: 2020 Tipo del documento: Article

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Hidradenitis Supurativa / Infliximab / Anticuerpos Monoclonales Tipo de estudio: Etiology_studies / Incidence_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Adult / Female / Humans / Male / Middle aged Idioma: En Revista: J Am Acad Dermatol Año: 2020 Tipo del documento: Article